key: cord-1024895-rsyuopdf
authors: Lacour, Thibaud; Semaan, Carl; Genet, Thibaud; Ivanes, Fabrice
title: Insights for increased risk of failed fibrinolytic therapy and stent thrombosis associated with COVID‐19 in ST‐segment elevation myocardial infarction patients
date: 2020-04-30
journal: Catheter Cardiovasc Interv
DOI: 10.1002/ccd.28948
sha: 485892380dae911d024446acee4205b3b53d6cf5
doc_id: 1024895
cord_uid: rsyuopdf

Important health resources are dedicated worldwide to the management of COVID‐19. This new disease, due to its large diffusion, may significantly hamper the prognosis of other pathologies, such as ST‐segment elevation myocardial infarction (STEMI) because of (a) a possible direct negative impact and (b) shortage of first response medical resources and increased delays to reperfusion. We report the case of a 68‐year‐old man admitted for anterior STEMI and asymptomatic COVID‐19. Due to extended transportation delays to a cathlab, he received intravenous fibrinolytic therapy, which failed. Reperfusion was achieved with rescue coronary angioplasty, but the patient experienced two episodes of acute stent thrombosis at 2‐ and 36‐hr following admission and despite optimal medical therapy. He finally died because of cardiogenic shock. This raises concerns about a possible increase in platelet aggregability associated with COVID‐19 leading to an increased risk of stent thrombosis, particularly in the context of STEMI. This pleads for the promotion of primary coronary angioplasty as the first‐choice revascularization technique in this population and the use of new generation P2Y12 inhibitors. In addition, the use of GPIIb/IIIa inhibitors may be considered in every STEMI patient with COVID‐19 to prevent the risk of acute stent thrombosis.

medical resources and increased delays to reperfusion. We report the case of a 68-year-old man admitted for anterior STEMI and asymptomatic COVID-19. Due to extended transportation delays to a cathlab, he received intravenous fibrinolytic therapy, which failed. Reperfusion was achieved with rescue coronary angioplasty, but the patient experienced two episodes of acute stent thrombosis at 2-and 36-hr following admission and despite optimal medical therapy. He finally died because of cardiogenic shock. This raises concerns about a possible increase in platelet aggregability associated with COVID-19 leading to an increased risk of stent thrombosis, particularly in the context of STEMI. This pleads for the promotion of primary coronary angioplasty as the first-choice revascularization technique in this population and the use of new generation P2Y12 inhibitors. In addition, the use of GPIIb/IIIa inhibitors may be considered in every STEMI patient with COVID-19 to prevent the risk of acute stent thrombosis. 20.5 min) compared to pre-pandemic activity. 3 Due to these increased delays, use of intravenous fibrinolytic therapy in STEMI is more often encouraged. 4, 5 But regarding the widespread of COVID-19 and the fact that many patients may be asymptomatic, this strategy may expose to significant worst outcomes in patients combining STEMI and COVID-19.

We report here the case of a patient admitted for acute anterior STEMI and who was secondarily diagnosed with COVID-19. 

Beside the post-fibrinolysis coagulation rebound that may induce acute coronary reocclusion, 6 we hypothesized that SARS-CoV-2 infection may have played a role in this unfavorable evolution.

COVID-19 has significant impacts on patients coagulation. 7 Yet, there is to date no description of COVID-19 impact on platelet function apart from the sepsis-associated intravascular disseminated coagulopathy with thrombocytopenia in case of severe infection. 8 In this case combining asymptomatic COVID-19 and STEMI, despite up-to-date optimal antithrombotic medical therapy, there seems to be an increase in the risk of stent thrombosis due to a possible excessive platelet aggregability. Considering the incidence of COVID-19 that is raising worldwide and the high prevalence of coronary artery disease, we may be exposed to a significant number of cases of patients experiencing STEMI and COVID-19 at the same time. We may even expect an increase in the incidence of STEMI as it is well accepted that acute viral infection increases the risk of acute myocardial infarction, mainly through acute inflammation and endothelial dysfunction. 9 suspected COVID-19 infection, even without high thrombotic burden, to prevent the risk of acute stent thrombosis.

Of course, we need data from large registries to confirm this suspected increased risk of stent thrombosis in these patients combining STEMI and COVID-19 and this report aims mainly to draw attention toward this particular situation that may become more and more frequent in our cardiology units.

Association of Coronavirus Disease 2019 (COVID-19) with myocardial injury and mortality

COVID-19 and the cardiovascular system

Impact of Coronavirus Disease 2019 (COVID-19) outbreak on ST-segment-elevation myocardial infarction Care in Hong Kong, China

Catheterization laboratory considerations during the coronavirus (COVID-19) pandemic: from ACC's interventional council and SCAI

How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People's Hospital

Platelet function during and after thrombolytic therapy for acute myocardial infarction with reteplase, alteplase, or streptokinase

Prominent changes in blood coagulation of patients with SARS-CoV-2 infection

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Viral and bacterial infections in patients with acute myocardial infarction

Risk of myocardial infarction and stroke after acute infection or vaccination

Insights for increased risk of failed fibrinolytic therapy and stent thrombosis associated with COVID-19 in ST-segment elevation myocardial infarction patients

We would like to acknowledge Dr Martine Ferrandière and Prof Denis Angoulvant for their assistance in the management of the patient.

The authors declare no conflicts of interest.

Fabrice Ivanes designed the work. Carl Semaan, Thibaud Genet, and Fabrice Ivanes analyzed and interpreted the data. Thibaud Lacour and Fabrice Ivanes wrote the manuscript. All the authors approved the final version.

https://orcid.org/0000-0003-2407-6387